Intensive GI: Unlock the Microbiome’s Power with Clinical Strains

The gut microbiota plays an essential role in our health by having important cross-talk with many organ systems in the body, including the skin, brain and kidneys. For gut health, probiotics have become specialized with strains utilizing novel mechanism of action. An area of particular interest in the field of gut health has been Irritable Bowel Syndrome, a growing condition afflicting 580 million people worldwide and a major women’s health matter (2 out 3 individuals with IBS are women).

Probiotic supplements for intestinal barrier support and gut health have long utilized a core group of familiar nutrients including glutamine, acetylglucosamine, vitamin D, prebiotic fibers, and deglycyrrhizinated licorice (DGL). Today, there is yet another potent option for optimal gut health and strengthened gut barrier: a multi-strain, Lactobacillus plantarum and Pediococcus acidilactisi formulation known as Intensive G.I. Recent evidence has illustrated the benefits of Intensive G.I. in different research models evaluating biomarkers related reduced gut pain sensitivity, improved quality of life, and reduction of gut anxiety.

Register for this webinar to learn about the 3 clinical strains in Intensive G.I.: two L. plantarum strains (KABP-022 and -023) and one Pediococcus acidilactisi strain. Also, participants will learn about related recent journal publications. We will cover the pathophysiology of IBS, including visceral hypersensitivity, increased mucosal permeability, and altered microbiome.

Intensive G.I. has been demonstrated to reduce gut-related discomfort and anxiety as well as strengthen the gut barrier. These mechanisms include enhancement of epithelial barrier function through production of polyphosphate granules and reduction of inflammation through acetate SCFA synthesis. Register for this webinar to learn about Intensive G.I.

Speaker

Robert J. Barry, Ph.D., Executive Director of Scientific Affairs, Kaneka

Dr. Barry focuses on clinical research development and collaboration and on the development of the technical, business and commercial translation of products and technology for Kaneka North America, a leading supplier of Ubiquinol, Coenzyme Q10 and Probiotics.

Dr. Barry was a Principal Advisor for NIH specializing in the commercial development of biotech start-up companies, their technologies and products. He also founded and served as president of a premier independent testing laboratory and scientific research company serving the natural products industry.

Dr. Barry earned his bachelor’s degree in biology from Boston College; his Ph.D. in chemistry/biochemistry from the University of Maryland; postdoctoral research in Biological Chemistry and Molecular Pharmacology at Harvard Medical School; and was a staff researcher in neuropathology at Harvard Medical School.

Message Presenter